Efficacy and infection morbidity of frontline immuno-chemotherapy in follicular lymphoma

Lymphoma
16/07/2020

Djebbari F, et al. Eur J Haematol 2020.

ABSTRACT

Current UK standard of care in frontline advanced stage (III or IV) symptomatic follicular lymphoma (FL) is immuno-chemotherapy with anti-CD20 monoclonal antibodies (mAbs) rituximab (R) or obinutuzumab (O), in combination with cyclophosphamide, vincristine and prednisolone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), or bendamustine (B)1 . Maintenance R or O are commonly offered to patients who achieved an objective response to induction1,2 .